Medicxi Ventures Management (Jersey) Ltd
Medicxi Ventures Management (Jersey) Ltd reported 3 US-listed holdings worth $177.4 million in its 13F for the quarter ended 30 June 2026, filed 4 August 2026. Its largest: Phathom Pharmaceuticals Inc. (45.6%), Newamsterdam Pharma Company (42.2%) and Aura Biosciences Inc. (12.2%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 1.
Filed before as Medicxi Ventures Management (Jersey) Ltd.
The 3 largest of its 3 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +98.7% over the 6 quarters to 31 March 2026, against +13.3% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- Newamsterdam Pharma Company NAMS-465,543 shares · -17%
Sold out of 1
- Centessa Pharmaceuticals PLC CNTA$792.9 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Phathom Pharmaceuticals Inc. PHAT | 7.5M | $81.0 million | 45.65% | no change |
| Newamsterdam Pharma Company NAMS | 2.2M | $74.9 million | 42.19% | -465.5K |
| Aura Biosciences Inc. AURA | 3.0M | $21.6 million | 12.16% | no change |